Vietnam.vn - Nền tảng quảng bá Việt Nam

EU approves HIV vaccine

The European Commission (EC) on August 26 licensed the HIV vaccine Lenacapavir from Gilead (USA), allowing it to be present in 27 EU countries as well as Norway, Iceland and Liechtenstein. However, the cost of vaccination is sky-high.

Báo Lào CaiBáo Lào Cai27/08/2025

HIV vaccine Lenacapavir.

HIV vaccine Lenacapavir.

According to Reuters, this two-dose/yearly injection will be sold in the European Union (EU) under the name Yeytuo, and is allowed to circulate in 27 member countries along with Norway, Iceland and Liechtenstein.

The EC approved the drug as pre-exposure prophylaxis (PrEP), to reduce the risk of sexually transmitted HIV infection in adults and adolescents at high risk of contracting the deadly virus.

Before the drug reaches patients, Gilead needs to finalize agreements on pricing and reimbursement mechanisms with each country's health system.

Lenacapavir proved nearly 100% effective in preventing HIV in large-scale trials last year, raising new hopes of stopping transmission of the virus that infects 1.3 million people a year.

Gilead said its application for EU market approval had been reviewed on an accelerated timetable, and was granted an additional year of market protection.

The company also said it has filed applications for Lenacapavir with regulators in Australia, Brazil, Canada, South Africa and Switzerland and is preparing applications in Argentina, Mexico and Peru.

The World Health Organization last July recommended Lenacapavir as an add-on option for HIV prevention.

Previously, the US Food and Drug Administration (FDA) approved Lenacapavir under the brand name Yeztugo, with a listed price of more than 28,000 USD for a year of treatment, equivalent to two injections.

But some US insurers are delaying coverage of Yeztugo, citing its exorbitant price tag compared to generics. Some analysts predict sales could reach more than $4 billion a year by 2029.

Gilead said it will pursue applications with regulators in low- and middle-income countries.

The company also plans to provide Lenacapavir to up to 2 million people in low-income countries over the next three years, together with the Global Fund to Fight AIDS, Tuberculosis and Malaria, according to Reuters.

tuoitre.vn

Source: https://baolaocai.vn/eu-da-cap-phep-cho-thuoc-tiem-phong-hiv-post880574.html


Comment (0)

No data
No data

Same tag

Same category

Visit U Minh Ha to experience green tourism in Muoi Ngot and Song Trem
Vietnam team promoted to FIFA rank after victory over Nepal, Indonesia in danger
71 years after liberation, Hanoi retains its heritage beauty in the modern flow
71st anniversary of Capital Liberation Day - stirring up the spirit for Hanoi to step firmly into the new era

Same author

Heritage

Figure

Enterprise

Vietnam team promoted to FIFA rank after victory over Nepal, Indonesia in danger

News

Political System

Destination

Product